North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) - Industry Trends and Forecast to 2030.
North America Uterine Cancer Diagnostics Market Analysis and Insights
Uterine cancer is the most common cancer that occurs in the female reproductive system. It is a malignant tumor that starts in the uterus cells and can spread to other body parts. According to research by the American Cancer Society (ACS), uterine sarcoma accounts for 5% of all uterine cancers worldwide, while endometrial cancer is the most common form of uterine cancer.
Data Bridge Market Research analyzes that the North America uterine cancer diagnostics market is expected to reach the value of USD 7,946.03 million by 2030, at a CAGR of 11.2% during the forecast period. Diagnostic type accounts for the largest segment in the market due to the increase in the obesity rate among the women population and rising uterine cancer patients North America. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2015)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Arquer Diagnostics Ltd, Guzip Biomarkers Corporation, General Electric, Canon Medical Systems ANZ Pty Limited., KARL STORZ, Medtronic, Stryker, Surtex Instruments Limited., Koninklijke Philips N.V., FUJIFILM Corporation, AED, Jalal Surgical, Integra LifeSciences, B. Braun Melsungen AG, and GRAIL among others
|
North America Uterine Cancer Diagnostics Market Definition
Diagnosis of uterine cancer includes ultrasound, biopsy procedures and blood tests. Ultrasound tests use sound waves and produce images of the ovaries and uterus. Two types of ultrasound are included in diagnostic testing for uterine cancer: abdominal ultrasound and transvaginal ultrasound. An abdominal scan test involves scanning the full bladder with a small probe across the abdomen, while a transvaginal scan involves inserting a probe tube into the vagina to scan or create an image. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation and curettage.
Cancer is one of the leading causes of death worldwide and the prevalence of this disease has increased at an alarming rate. Therefore, health professionals are focusing on developing effective screening and treatment solutions to control obesity rates. Moreover, an endometrial biopsy involves removing some malignant tissue from the endometrium and sending it for a testing procedure. The growing number of geriatric women in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic market.
North America Uterine Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail below:
Drivers
- Technological advancements in uterine cancer diagnostics
Uterine cancer is a ubiquitous gynaecological disease with many tests available for diagnosis, which include pelvic examination, endometrial biopsy, Dilation and Curettage (D&C), Transvaginal ultrasound, Computed Tomography (CT or CAT) scan, Magnetic Resonance Imaging (MRI) and biomarker testing of the tumor. Traditional means of detecting and monitoring cancers rely largely on imaging and, where possible, blood-based protein biomarkers, many of which are non-specific. Most cases of uterine cancer are diagnosed at late stages, as the presenting symptoms are often non-specific. The signs and symptoms of uterine cancer vary from person to person, making it difficult to provide accurate early diagnosis. This calls for personalized diagnostic plans, which involve multiple diagnostic tests.
Thus, technological advancements in uterine cancer diagnostics are expected to drive the market's growth.
- Rising demand for minimally invasive advanced screening techniques
Uterine cancer, especially endometrial cancer, is the fifth most common cancer in women in very high human development index regions based on age-standardized rates and its incidence has increased over the last few years. The standard strategy to diagnose endometrial cancer consists of office-based pelvic ultrasonography plus endometrial papilla sampling in cases of increased endometrial thickness. A hysteroscopy is recommended when the diagnosis is uncertain. Limitations include sample insufficiency in unsuccessful insertions (on occasions due to cervical stenosis or prolapse) and as well an abnormal sonographic appearance of the endometrium. Hence several limitations are associated with so-called standard methods of a uterine cancer diagnosis.
Thus, rising demand for minimally invasive advanced screening techniques are expected to drive the market's growth.
Restraint
- High risk complications during diagnostic tests
Several screening tests are used for detecting uterine cancers, which include the PAP test, transvaginal ultrasound and endometrial sampling (biopsy) among others. Although these tests are considered standard for diagnosing uterine cancer, they have their associated risks, including false-negative and false-positive results and side effects such as bleeding, discomfort, infection and puncture of the uterus.
As mentioned above, many complications are associated with the current diagnostic and screening tests for uterine cancer, which are keeping patients at further risk. These risks are expected to restrain the growth of the North America uterine cancer diagnostics market.
Opportunity
- Increasing prevalence of uterine cancer
Uterine cancer is the most common type of gynecologic cancer. Over 90% of uterine cancers begin in the endometrium, the tissue lining the uterus. As the prevalence is increasing, the introduction of promising new treatments and therapeutic biologics and the rapid growth of hormone-resistant cancer drugs due to fewer side effects are also increasing. Awareness of the incidence of uterine cancer is growing among patients and healthcare providers, who are now becoming more active in learning about the diagnosis and treatments available for these diseases, which is expected to act as an opportunity for the market's growth.
Rates of new uterine cancer cases have risen 0.6% per year from 2010-2019 and death rates have risen an average of 1.7% per year for the /corp.html">same time frame. As the uterine cancer patient rate is increasing, the use of treatments and advanced technologies for cancer diagnosis will increase, which is an opportunity for market growth.
Challenge
- Lack of diagnostic infrastructure
Non-communicable diseases such as uterine cancer and other types of cancer have now been recognized by the United Nations and WHO as major public health crises. Cancer is the biggest part of this problem and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approaches and outcomes between high-income countries and low and middle-income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps and lack of awareness among the lay and medical community. Diagnosis and treatment play an important role in this complex environment. Different regions and countries of the world have different health systems, but most of them are fragmented or poorly coordinated. There is an urgent need to expand cancer care in low- and middle-income countries.
Post-COVID-19 Impact on North America Uterine Cancer Diagnostics Market
The COVID-19 pandemic has caused disruptions in elective health services related to uterine screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of uterine cancer, exacerbating existing health inequalities.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launches and strategic partnerships to improve the technology and test results involved in the North America uterine cancer diagnostics market.
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the North America launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. it is portable and versatile with good image quality or performance. it is compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio
- In April 2022, Medtronic and GE Healthcare announced a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). Because of this collaboration, customers can access extensive product portfolios, financial solutions and exceptional service. GE Healthcare Interventional Imaging solutions are built to help our customers deliver care at a higher level for patients, which is very useful of cancer patients. This has helped the company to expand its business
North America Uterine Cancer Diagnostics Market Scope
North America uterine cancer diagnostics market is segmented into diagnostic type, type, age group, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY DIAGNOSTIC TYPE
- Instrument Based
- Procedure Based
On the basis of diagnostic type, the North America uterine cancer diagnostic market is segmented into instrument based and procedure based.
BY TYPE
- Endometrial Cancer
- Uterine Sarcoma
On the basis of type, the North America uterine cancer diagnostic market is segmented into endometrial cancer and uterine sarcoma.
BY AGE GROUP
- <30 years
- 31-40 years
- 41-50 years
- 51-60 years
- >60 years
On the basis of age group, the North America uterine cancer diagnostic market is segmented into <30, 31-40, 41-50, 51-60 and >60.
BY END USER
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Ambulatory Surgical Centers
- Specialized Clinics
- Others
On the basis of end user, the North America uterine cancer diagnostic market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, specialized clinics and others.
BY DISTRIBUTION CHANNEL
- Direct Tenders
- Third Party Distributors
- Others
On the basis of distribution channel, the North America uterine cancer diagnostic market is segmented into direct tender, third party distributors and others.
North America Uterine Cancer Diagnostics Market Regional Analysis/Insights
The North America uterine cancer diagnostics market is analyzed and market size information is provided diagnostic type, type, age group, end user and distribution channel.
The countries covered in this market report are the U.S., Canada, and Mexico.
U.S is expected to dominate the North America uterine cancer diagnostics market due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced cancer diagnostic technology and inventions in uterine cancer diagnostics.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Uterine Cancer Diagnostics Market Share Analysis
North America uterine cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus on the North America uterine cancer diagnostics market.
Some of the major players operating in the North America uterine cancer diagnostics market are F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Arquer Diagnostics Ltd, Guzip Biomarkers Corporation, General Electric, Canon Medical Systems ANZ Pty Limited., KARL STORZ, Medtronic, Stryker, Surtex Instruments Limited., Koninklijke Philips N.V., FUJIFILM Corporation, AED, Jalal Surgical, Integra LifeSciences, B. Braun Melsungen AG, and GRAIL among others.
SKU-